Characteristics and outcomes of an international cohort of 600 000 hospitalized patients with COVID-19
© The Author(s) 2023. Published by Oxford University Press on behalf of the International Epidemiological Association..
BACKGROUND: We describe demographic features, treatments and clinical outcomes in the International Severe Acute Respiratory and emerging Infection Consortium (ISARIC) COVID-19 cohort, one of the world's largest international, standardized data sets concerning hospitalized patients.
METHODS: The data set analysed includes COVID-19 patients hospitalized between January 2020 and January 2022 in 52 countries. We investigated how symptoms on admission, co-morbidities, risk factors and treatments varied by age, sex and other characteristics. We used Cox regression models to investigate associations between demographics, symptoms, co-morbidities and other factors with risk of death, admission to an intensive care unit (ICU) and invasive mechanical ventilation (IMV).
RESULTS: Data were available for 689 572 patients with laboratory-confirmed (91.1%) or clinically diagnosed (8.9%) SARS-CoV-2 infection from 52 countries. Age [adjusted hazard ratio per 10 years 1.49 (95% CI 1.48, 1.49)] and male sex [1.23 (1.21, 1.24)] were associated with a higher risk of death. Rates of admission to an ICU and use of IMV increased with age up to age 60 years then dropped. Symptoms, co-morbidities and treatments varied by age and had varied associations with clinical outcomes. The case-fatality ratio varied by country partly due to differences in the clinical characteristics of recruited patients and was on average 21.5%.
CONCLUSIONS: Age was the strongest determinant of risk of death, with a ∼30-fold difference between the oldest and youngest groups; each of the co-morbidities included was associated with up to an almost 2-fold increase in risk. Smoking and obesity were also associated with a higher risk of death. The size of our international database and the standardized data collection method make this study a comprehensive international description of COVID-19 clinical features. Our findings may inform strategies that involve prioritization of patients hospitalized with COVID-19 who have a higher risk of death.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:52 |
|---|---|
| Enthalten in: |
International journal of epidemiology - 52(2023), 2 vom: 19. Apr., Seite 355-376 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kartsonaki, Christiana [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Completed 20.04.2023 Date Revised 20.03.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/ije/dyad012 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM353561835 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM353561835 | ||
| 003 | DE-627 | ||
| 005 | 20240320233008.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/ije/dyad012 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1337.xml |
| 035 | |a (DE-627)NLM353561835 | ||
| 035 | |a (NLM)36850054 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kartsonaki, Christiana |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Characteristics and outcomes of an international cohort of 600 000 hospitalized patients with COVID-19 |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.04.2023 | ||
| 500 | |a Date Revised 20.03.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2023. Published by Oxford University Press on behalf of the International Epidemiological Association. | ||
| 520 | |a BACKGROUND: We describe demographic features, treatments and clinical outcomes in the International Severe Acute Respiratory and emerging Infection Consortium (ISARIC) COVID-19 cohort, one of the world's largest international, standardized data sets concerning hospitalized patients | ||
| 520 | |a METHODS: The data set analysed includes COVID-19 patients hospitalized between January 2020 and January 2022 in 52 countries. We investigated how symptoms on admission, co-morbidities, risk factors and treatments varied by age, sex and other characteristics. We used Cox regression models to investigate associations between demographics, symptoms, co-morbidities and other factors with risk of death, admission to an intensive care unit (ICU) and invasive mechanical ventilation (IMV) | ||
| 520 | |a RESULTS: Data were available for 689 572 patients with laboratory-confirmed (91.1%) or clinically diagnosed (8.9%) SARS-CoV-2 infection from 52 countries. Age [adjusted hazard ratio per 10 years 1.49 (95% CI 1.48, 1.49)] and male sex [1.23 (1.21, 1.24)] were associated with a higher risk of death. Rates of admission to an ICU and use of IMV increased with age up to age 60 years then dropped. Symptoms, co-morbidities and treatments varied by age and had varied associations with clinical outcomes. The case-fatality ratio varied by country partly due to differences in the clinical characteristics of recruited patients and was on average 21.5% | ||
| 520 | |a CONCLUSIONS: Age was the strongest determinant of risk of death, with a ∼30-fold difference between the oldest and youngest groups; each of the co-morbidities included was associated with up to an almost 2-fold increase in risk. Smoking and obesity were also associated with a higher risk of death. The size of our international database and the standardized data collection method make this study a comprehensive international description of COVID-19 clinical features. Our findings may inform strategies that involve prioritization of patients hospitalized with COVID-19 who have a higher risk of death | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a co-morbidities | |
| 650 | 4 | |a cohort study | |
| 650 | 4 | |a risk of death | |
| 650 | 4 | |a symptoms | |
| 650 | 4 | |a treatments | |
| 700 | 1 | |a Baillie, J Kenneth |e verfasserin |4 aut | |
| 700 | 1 | |a Barrio, Noelia García |e verfasserin |4 aut | |
| 700 | 1 | |a Baruch, Joaquín |e verfasserin |4 aut | |
| 700 | 1 | |a Beane, Abigail |e verfasserin |4 aut | |
| 700 | 1 | |a Blumberg, Lucille |e verfasserin |4 aut | |
| 700 | 1 | |a Bozza, Fernando |e verfasserin |4 aut | |
| 700 | 1 | |a Broadley, Tessa |e verfasserin |4 aut | |
| 700 | 1 | |a Burrell, Aidan |e verfasserin |4 aut | |
| 700 | 1 | |a Carson, Gail |e verfasserin |4 aut | |
| 700 | 1 | |a Citarella, Barbara Wanjiru |e verfasserin |4 aut | |
| 700 | 1 | |a Dagens, Andrew |e verfasserin |4 aut | |
| 700 | 1 | |a Dankwa, Emmanuelle A |e verfasserin |4 aut | |
| 700 | 1 | |a Donnelly, Christl A |e verfasserin |4 aut | |
| 700 | 1 | |a Dunning, Jake |e verfasserin |4 aut | |
| 700 | 1 | |a Elotmani, Loubna |e verfasserin |4 aut | |
| 700 | 1 | |a Escher, Martina |e verfasserin |4 aut | |
| 700 | 1 | |a Farshait, Nataly |e verfasserin |4 aut | |
| 700 | 1 | |a Goffard, Jean-Christophe |e verfasserin |4 aut | |
| 700 | 1 | |a Gonçalves, Bronner P |e verfasserin |4 aut | |
| 700 | 1 | |a Hall, Matthew |e verfasserin |4 aut | |
| 700 | 1 | |a Hashmi, Madiha |e verfasserin |4 aut | |
| 700 | 1 | |a Sim Lim Heng, Benedict |e verfasserin |4 aut | |
| 700 | 1 | |a Ho, Antonia |e verfasserin |4 aut | |
| 700 | 1 | |a Jassat, Waasila |e verfasserin |4 aut | |
| 700 | 1 | |a Pedrera Jiménez, Miguel |e verfasserin |4 aut | |
| 700 | 1 | |a Laouenan, Cedric |e verfasserin |4 aut | |
| 700 | 1 | |a Lissauer, Samantha |e verfasserin |4 aut | |
| 700 | 1 | |a Martin-Loeches, Ignacio |e verfasserin |4 aut | |
| 700 | 1 | |a Mentré, France |e verfasserin |4 aut | |
| 700 | 1 | |a Merson, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Morton, Ben |e verfasserin |4 aut | |
| 700 | 1 | |a Munblit, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Nekliudov, Nikita A |e verfasserin |4 aut | |
| 700 | 1 | |a Nichol, Alistair D |e verfasserin |4 aut | |
| 700 | 1 | |a Singh Oinam, Budha Charan |e verfasserin |4 aut | |
| 700 | 1 | |a Ong, David |e verfasserin |4 aut | |
| 700 | 1 | |a Panda, Prasan Kumar |e verfasserin |4 aut | |
| 700 | 1 | |a Petrovic, Michele |e verfasserin |4 aut | |
| 700 | 1 | |a Pritchard, Mark G |e verfasserin |4 aut | |
| 700 | 1 | |a Ramakrishnan, Nagarajan |e verfasserin |4 aut | |
| 700 | 1 | |a Ramos, Grazielle Viana |e verfasserin |4 aut | |
| 700 | 1 | |a Roger, Claire |e verfasserin |4 aut | |
| 700 | 1 | |a Sandulescu, Oana |e verfasserin |4 aut | |
| 700 | 1 | |a Semple, Malcolm G |e verfasserin |4 aut | |
| 700 | 1 | |a Sharma, Pratima |e verfasserin |4 aut | |
| 700 | 1 | |a Sigfrid, Louise |e verfasserin |4 aut | |
| 700 | 1 | |a Somers, Emily C |e verfasserin |4 aut | |
| 700 | 1 | |a Streinu-Cercel, Anca |e verfasserin |4 aut | |
| 700 | 1 | |a Taccone, Fabio |e verfasserin |4 aut | |
| 700 | 1 | |a Vecham, Pavan Kumar |e verfasserin |4 aut | |
| 700 | 1 | |a Kumar Tirupakuzhi Vijayaraghavan, Bharath |e verfasserin |4 aut | |
| 700 | 1 | |a Wei, Jia |e verfasserin |4 aut | |
| 700 | 1 | |a Wils, Evert-Jan |e verfasserin |4 aut | |
| 700 | 1 | |a Ci Wong, Xin |e verfasserin |4 aut | |
| 700 | 1 | |a Horby, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Rojek, Amanda |e verfasserin |4 aut | |
| 700 | 1 | |a Olliaro, Piero L |e verfasserin |4 aut | |
| 700 | 0 | |a ISARIC Clinical Characterisation Group |e verfasserin |4 aut | |
| 700 | 1 | |a Abbas, Ali |e investigator |4 oth | |
| 700 | 1 | |a Abdukahil, Sheryl Ann |e investigator |4 oth | |
| 700 | 1 | |a Abdulkadir, Nurul Najmee |e investigator |4 oth | |
| 700 | 1 | |a Abe, Ryuzo |e investigator |4 oth | |
| 700 | 1 | |a Abel, Laurent |e investigator |4 oth | |
| 700 | 1 | |a Absil, Lara |e investigator |4 oth | |
| 700 | 1 | |a Acharya, Subhash |e investigator |4 oth | |
| 700 | 1 | |a Acker, Andrew |e investigator |4 oth | |
| 700 | 1 | |a Adam, Elisabeth |e investigator |4 oth | |
| 700 | 1 | |a Adrião, Diana |e investigator |4 oth | |
| 700 | 1 | |a Al Ageel, Saleh |e investigator |4 oth | |
| 700 | 1 | |a Ahmed, Shakeel |e investigator |4 oth | |
| 700 | 1 | |a Ainscough, Kate |e investigator |4 oth | |
| 700 | 1 | |a Airlangga, Eka |e investigator |4 oth | |
| 700 | 1 | |a Aisa, Tharwat |e investigator |4 oth | |
| 700 | 1 | |a Hssain, Ali Ait |e investigator |4 oth | |
| 700 | 1 | |a Tamlihat, Younes Ait |e investigator |4 oth | |
| 700 | 1 | |a Akimoto, Takako |e investigator |4 oth | |
| 700 | 1 | |a Akmal, Ernita |e investigator |4 oth | |
| 700 | 1 | |a Al Qasim, Eman |e investigator |4 oth | |
| 700 | 1 | |a Alalqam, Razi |e investigator |4 oth | |
| 700 | 1 | |a Alberti, Angela |e investigator |4 oth | |
| 700 | 1 | |a Al-Dabbous, Tala |e investigator |4 oth | |
| 700 | 1 | |a Alegesan, Senthilkumar |e investigator |4 oth | |
| 700 | 1 | |a Alegre, Cynthia |e investigator |4 oth | |
| 700 | 1 | |a Alessi, Marta |e investigator |4 oth | |
| 700 | 1 | |a Alex, Beatrice |e investigator |4 oth | |
| 700 | 1 | |a Alexandre, Kévin |e investigator |4 oth | |
| 700 | 1 | |a Al-Fares, Abdulrahman |e investigator |4 oth | |
| 700 | 1 | |a Alfoudri, Huda |e investigator |4 oth | |
| 700 | 1 | |a Ali, Imran |e investigator |4 oth | |
| 700 | 1 | |a Ali, Adam |e investigator |4 oth | |
| 700 | 1 | |a Shah, Naseem Ali |e investigator |4 oth | |
| 700 | 1 | |a Alidjnou, Kazali Enagnon |e investigator |4 oth | |
| 700 | 1 | |a Aliudin, Jeffrey |e investigator |4 oth | |
| 700 | 1 | |a Alkhafajee, Qabas |e investigator |4 oth | |
| 700 | 1 | |a Allavena, Clotilde |e investigator |4 oth | |
| 700 | 1 | |a Allou, Nathalie |e investigator |4 oth | |
| 700 | 1 | |a Altaf, Aneela |e investigator |4 oth | |
| 700 | 1 | |a Alves, João |e investigator |4 oth | |
| 700 | 1 | |a Alves, Rita |e investigator |4 oth | |
| 700 | 1 | |a Alves, João Melo |e investigator |4 oth | |
| 700 | 1 | |a Amaral, Maria |e investigator |4 oth | |
| 700 | 1 | |a Amira, Nur |e investigator |4 oth | |
| 700 | 1 | |a Ampaw, Phoebe |e investigator |4 oth | |
| 700 | 1 | |a Andini, Roberto |e investigator |4 oth | |
| 700 | 1 | |a Andréjak, Claire |e investigator |4 oth | |
| 700 | 1 | |a Angheben, Andrea |e investigator |4 oth | |
| 700 | 1 | |a Angoulvant, François |e investigator |4 oth | |
| 700 | 1 | |a Ansart, Séverine |e investigator |4 oth | |
| 700 | 1 | |a Anthonidass, Sivanesen |e investigator |4 oth | |
| 700 | 1 | |a Antonelli, Massimo |e investigator |4 oth | |
| 700 | 1 | |a de Brito, Carlos Alexandre Antunes |e investigator |4 oth | |
| 700 | 1 | |a Apriyana, Ardiyan |e investigator |4 oth | |
| 700 | 1 | |a Arabi, Yaseen |e investigator |4 oth | |
| 700 | 1 | |a Aragao, Irene |e investigator |4 oth | |
| 700 | 1 | |a Arancibia, Francisco |e investigator |4 oth | |
| 700 | 1 | |a Araujo, Carolline |e investigator |4 oth | |
| 700 | 1 | |a Arcadipane, Antonio |e investigator |4 oth | |
| 700 | 1 | |a Archambault, Patrick |e investigator |4 oth | |
| 700 | 1 | |a Arenz, Lukas |e investigator |4 oth | |
| 700 | 1 | |a Arlet, Jean-Benoît |e investigator |4 oth | |
| 700 | 1 | |a Arnold-Day, Christel |e investigator |4 oth | |
| 700 | 1 | |a Arora, Lovkesh |e investigator |4 oth | |
| 700 | 1 | |a Arora, Rakesh |e investigator |4 oth | |
| 700 | 1 | |a Artaud-Macari, Elise |e investigator |4 oth | |
| 700 | 1 | |a Aryal, Diptesh |e investigator |4 oth | |
| 700 | 1 | |a Asensio, Angel |e investigator |4 oth | |
| 700 | 1 | |a Ashraf, Muhammad |e investigator |4 oth | |
| 700 | 1 | |a Asif, Namra |e investigator |4 oth | |
| 700 | 1 | |a Asim, Mohammad |e investigator |4 oth | |
| 700 | 1 | |a Assie, Jean Baptiste |e investigator |4 oth | |
| 700 | 1 | |a Asyraf, Amirul |e investigator |4 oth | |
| 700 | 1 | |a Atique, Anika |e investigator |4 oth | |
| 700 | 1 | |a Attanyake, A M Udara Lakshan |e investigator |4 oth | |
| 700 | 1 | |a Auchabie, Johann |e investigator |4 oth | |
| 700 | 1 | |a Aumaitre, Hugues |e investigator |4 oth | |
| 700 | 1 | |a Auvet, Adrien |e investigator |4 oth | |
| 700 | 1 | |a Azemar, Laurène |e investigator |4 oth | |
| 700 | 1 | |a Azoulay, Cecile |e investigator |4 oth | |
| 700 | 1 | |a Bach, Benjamin |e investigator |4 oth | |
| 700 | 1 | |a Bachelet, Delphine |e investigator |4 oth | |
| 700 | 1 | |a Badr, Claudine |e investigator |4 oth | |
| 700 | 1 | |a Baig, Nadia |e investigator |4 oth | |
| 700 | 1 | |a Baird, J Kevin |e investigator |4 oth | |
| 700 | 1 | |a Bak, Erica |e investigator |4 oth | |
| 700 | 1 | |a Bakakos, Agamemnon |e investigator |4 oth | |
| 700 | 1 | |a Bakar, Nazreen Abu |e investigator |4 oth | |
| 700 | 1 | |a Bal, Andriy |e investigator |4 oth | |
| 700 | 1 | |a Balakrishnan, Mohanaprasanth |e investigator |4 oth | |
| 700 | 1 | |a Balan, Valeria |e investigator |4 oth | |
| 700 | 1 | |a Bani-Sadr, Firouzé |e investigator |4 oth | |
| 700 | 1 | |a Barbalho, Renata |e investigator |4 oth | |
| 700 | 1 | |a Barbosa, Nicholas Yuri |e investigator |4 oth | |
| 700 | 1 | |a Barclay, Wendy S |e investigator |4 oth | |
| 700 | 1 | |a Barnett, Saef Umar |e investigator |4 oth | |
| 700 | 1 | |a Barnikel, Michaela |e investigator |4 oth | |
| 700 | 1 | |a Barrasa, Helena |e investigator |4 oth | |
| 700 | 1 | |a Barrelet, Audrey |e investigator |4 oth | |
| 700 | 1 | |a Barrigoto, Cleide |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of epidemiology |d 1975 |g 52(2023), 2 vom: 19. Apr., Seite 355-376 |w (DE-627)NLM00011930X |x 1464-3685 |7 nnns |
| 773 | 1 | 8 | |g volume:52 |g year:2023 |g number:2 |g day:19 |g month:04 |g pages:355-376 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/ije/dyad012 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 52 |j 2023 |e 2 |b 19 |c 04 |h 355-376 | ||